BioCentury
ARTICLE | Company News

Dynavax, National Institutes of Health infectious news

October 6, 2008 7:00 AM UTC

Dynavax received a five-year, $17 million contract from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccine adjuvant candidates for anthrax and other disease. Dynava...